277 related articles for article (PubMed ID: 24122122)
1. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K; Asahina Y; Matsuda S; Muraoka M; Nakata T; Suzuki Y; Tamaki N; Yasui Y; Suzuki S; Hosokawa T; Nishimura T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Cancer; 2014 Jan; 120(2):229-37. PubMed ID: 24122122
[TBL] [Abstract][Full Text] [Related]
2. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
[TBL] [Abstract][Full Text] [Related]
3. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
4. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
5. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
7. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Itokawa N; Atsukawa M; Tsubota A; Okubo T; Arai T; Nakagawa A; Kondo C; Iwakiri K
Int J Clin Oncol; 2016 Aug; 21(4):676-683. PubMed ID: 26701173
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Cao G; Li X; Qin C; Li J
Med Sci Monit; 2015 Oct; 21():3144-51. PubMed ID: 26476711
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Doyle A; Marsh P; Gill R; Rodov M; Mohsen W; Varma P; Hong T; Strasser SI; Bell S; Ryan M; Nicoll A; Lubel J; Gow PJ; Fink MA; Roberts S; Kemp W; Kronborg I; Arachchi N; Knight V; Dev A
Scand J Gastroenterol; 2016 Aug; 51(8):979-85. PubMed ID: 27161568
[TBL] [Abstract][Full Text] [Related]
12. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
He K; Yang Z; Liu X; Yang Y; Song W; Wang S; Chen Y
Curr Oncol; 2022 Dec; 30(1):476-491. PubMed ID: 36661687
[TBL] [Abstract][Full Text] [Related]
13. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Jun; 33(3):729-39. PubMed ID: 25861764
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
16. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
Køstner AH; Sorensen M; Olesen RK; Grønbæk H; Lassen U; Ladekarl M
ScientificWorldJournal; 2013; 2013():931972. PubMed ID: 23431262
[TBL] [Abstract][Full Text] [Related]
19. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
20. [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Shinohara M; Kikuchi Y; Igarashi Y; Sumino Y
Gan To Kagaku Ryoho; 2016 Jul; 43(7):863-7. PubMed ID: 27431630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
